A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer.
about
Histological and molecular evaluation of patient-derived colorectal cancer explantsCharacterization of rare transforming KRAS mutations in sporadic colorectal cancer.No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis.KRAS mutation testing in metastatic colorectal cancerBevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer.Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significanceHow close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation.New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs.Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review.The war on cancer: are we winning?Precision treatment for cancer: role of prognostic and predictive markers.Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?KRAS mutation testing in clinical practice.Personalized treatment for patients with colorectal cancer: role of biomarkers.Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies.Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.The molecular heterogeneity of sporadic colorectal cancer with different tumor sites in Chinese patients.KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer.Mutational analysis of KRAS and its clinical implications in cervical cancer patients.Natural killer cells activity in a metastatic colorectal cancer patient with complete and long lasting response to therapy.Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.Molecular Biomarkers for the Evaluation of Colorectal Cancer.[Molecular pathology of colorectal cancer].
P2860
Q21134541-EA77E7C4-93D6-404F-AA23-146437947B2FQ33727871-D2DEBEB7-CD0F-4734-887D-69ED42070CFFQ34506141-19623362-7F49-4EF1-917F-0ADFC83BA91AQ34643960-C33FF2B6-4BF6-41F4-92F9-233D4C0EB1E9Q34654266-BB4771BF-C5DE-4951-BC83-639A32B392C4Q36977022-F3A209FA-E1D6-442A-862B-3DA295D11E2DQ37385227-CF03FEF6-9119-4CCC-A6A7-49D880BFD56EQ37457496-A5BFF10B-250F-4D35-82F3-D90F0C0695C1Q37600051-A5491A3D-75C3-47B7-8B36-1DFC49365F43Q37724947-5AD65661-E461-4247-A746-732994EAF5D6Q38075848-01E927FD-4E62-45E9-BD01-90459C05BA42Q38097382-532B80DB-97F4-454E-965A-EBDB3D879B61Q38179024-4AC989E0-D2E5-412F-96A8-E3A32153AA75Q38239192-51FC366A-73C5-4F88-9813-A673C1AD30F2Q38268569-234A6371-70A8-4C5E-9D33-4997C263C71DQ38285393-A3A02D8E-10E6-4D8F-87E6-38582B9950E3Q38390834-484E3E63-1B63-4E21-8134-322200F80B79Q39051337-D6C8FE31-B665-4A01-BAA7-16F00EE58916Q39347386-1881821E-5D1A-4311-AD5E-ACEDA4369B5AQ40341349-70834DE4-0B4C-4089-8DE6-4DDDC5A7117AQ41472303-C5341C16-1B56-4F79-AA3D-F747BC4D7595Q41949668-E90D6376-9179-4B86-831B-93058D41C3CEQ47140117-6A69048B-978F-4C33-8CCC-3A3D4FA5C6F3Q47153507-522EFFDF-AE3D-4091-83B7-FD553A6AF435Q48254405-B5CF3791-949F-4C75-86CA-1703370ED601Q52794464-EE010D91-E024-492F-8C55-294B7ED574BBQ53581884-9FF81EF3-7930-4F24-8EF2-7AE9A0A63A09
P2860
A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A systematic review and meta-a ...... metastatic colorectal cancer.
@en
A systematic review and meta-a ...... metastatic colorectal cancer.
@nl
type
label
A systematic review and meta-a ...... metastatic colorectal cancer.
@en
A systematic review and meta-a ...... metastatic colorectal cancer.
@nl
prefLabel
A systematic review and meta-a ...... metastatic colorectal cancer.
@en
A systematic review and meta-a ...... metastatic colorectal cancer.
@nl
P50
P921
P1476
A systematic review and meta-a ...... metastatic colorectal cancer.
@en
P2093
Carole A Harris
P304
P356
10.1016/J.EJCA.2011.03.031
P577
2011-05-05T00:00:00Z